$TDOC
Teladoc Health, Inc. Stock $tdoc

$tdoc Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000155837020001473 Filed on February 26, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019
Revenue	$180.8M	$156.5M	$553.3M
YoY Change	40.62%	27.5%	32.4%
Cost Of Revenue	$72.38M	$55.36M	$184.5M
YoY Change	62.01%	38.29%	43.29%
Gross Profit	$108.4M	$101.1M	$368.8M
YoY Change	29.23%	22.27%	27.55%
Gross Profit Margin	59.97%	64.63%	66.66%
Selling, General & Admin	$64.28M	$61.23M	$229.4M
YoY Change	23.16%	20.14%	30.27%
% of Gross Profit	59.29%	60.55%	62.19%
Research & Development	$19.26M	$16.25M	$64.64M
YoY Change	20.45%	19.95%	18.89%
% of Gross Profit	17.76%	16.06%	17.53%
Depreciation & Amortization	$9.710M	$11.09M	$38.95M
YoY Change	-16.03%	16.13%	9.41%
% of Gross Profit	8.96%	10.97%	10.56%
Operating Expenses	$83.54M	$77.48M	$294.0M
YoY Change	22.53%	20.1%	27.59%
Operating Profit	-$21.01M	-$15.59M	-$80.44M
YoY Change	-8.2%	-12.61%	13.53%
Interest Expense	-$9.300M	-$7.600M	-$29.00M
YoY Change	43.08%	13.43%	11.11%
% of Operating Profit
Other Income/Expense, Net	-$685.0K		$342.0K
YoY Change
Pretax Income	-$30.31M	-$23.17M	-$109.5M
YoY Change	3.08%	-5.43%	12.88%
Income Tax	-$700.0K	-$4.125M	-$10.59M
% Of Pretax Income
Net Earnings	-$29.60M	-$19.04M	-$98.86M
YoY Change	-1.81%	-23.45%	1.83%
Net Earnings / Revenue	-16.37%	-12.17%	-17.87%
Basic Earnings Per Share			-$1.38
Diluted Earnings Per Share	-$403.8K	-$261.7K	-$1.38
COMMON SHARES
Basic Shares Outstanding	73.01M	72.38M	71.85M
Diluted Shares Outstanding			71.85M

Balance Sheet

Concept	2020 Q1	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$510.8M	$517.1M	$517.0M
YoY Change	6.41%	8.05%	7.93%
Cash & Equivalents	$508.0M	$514.4M	$514.0M
Short-Term Investments	$2.819M	$2.711M	$3.000M
Other Short-Term Assets	$15.00M	$14.00M	$14.00M
YoY Change	36.36%	27.27%	27.27%
Inventory		$0.00
Prepaid Expenses
Receivables	$70.70M	$56.95M	$57.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$596.4M	$588.0M	$588.0M
YoY Change	10.25%	10.37%	10.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.09M	$10.30M	$37.00M
YoY Change	-72.72%	1.46%	270.0%
Goodwill	$734.4M	$746.1M
YoY Change		1.2%
Intangibles	$214.7M	$225.5M
YoY Change		-8.87%
Long-Term Investments
YoY Change
Other Assets	$15.33M	$6.545M	$7.000M
YoY Change	1433.0%	367.17%	600.0%
Total Long-Term Assets	$1.007B	$1.015B	$1.015B
YoY Change	-0.43%	1.88%	1.91%
TOTAL ASSETS
Total Short-Term Assets	$596.4M	$588.0M	$588.0M
Total Long-Term Assets	$1.007B	$1.015B	$1.015B
Total Assets	$1.603B	$1.603B	$1.603B
YoY Change	3.29%	4.84%	4.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.142M	$9.075M	$9.000M
YoY Change	1.78%	16.81%	12.5%
Accrued Expenses	$54.00M	$58.00M	$58.00M
YoY Change	31.71%	41.46%	41.46%
Deferred Revenue	$17.87M	$12.47M
YoY Change		62.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$97.16M	$90.18M	$90.00M
YoY Change	34.95%	44.43%	45.16%
LONG-TERM LIABILITIES
Long-Term Debt	$447.0M	$440.0M	$440.0M
YoY Change	6.18%	6.02%	6.02%
Other Long-Term Liabilities	$10.24M	$9.239M	$37.00M
YoY Change	-63.44%	49.23%	516.67%
Total Long-Term Liabilities	$10.24M	$9.239M	$477.0M
YoY Change	-97.72%	49.23%	13.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$97.16M	$90.18M	$90.00M
Total Long-Term Liabilities	$10.24M	$9.239M	$477.0M
Total Liabilities	$107.4M	$99.42M	$589.0M
YoY Change	-80.47%	44.86%	14.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$537.1M	-$507.5M
YoY Change		24.19%
Common Stock	$1.572B	$1.539B
YoY Change		7.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.000B	$1.014B	$1.014B
YoY Change
Total Liabilities & Shareholders Equity	$1.603B	$1.603B	$1.603B
YoY Change	3.29%	4.84%	4.84%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$29.60M	-$19.04M	-$98.86M
YoY Change	-1.81%	-23.45%	1.83%
Depreciation, Depletion And Amortization	$9.710M	$11.09M	$38.95M
YoY Change	-16.03%	16.13%	9.41%
Cash From Operating Activities	-$6.320M	$18.12M	$29.87M
YoY Change	-19.92%	630.65%	-714.59%
INVESTING ACTIVITIES
Capital Expenditures	$962.0K	-$3.390M	$3.510M
YoY Change	68.48%	16.1%	-12.49%
Acquisitions	$9.000M		$11.19M
YoY Change			-96.04%
Other Investing Activities	$0.00	$12.94M	$0.00
YoY Change	-100.0%	-132.82%	-100.0%
Cash From Investing Activities	-$11.93M	$9.540M	$25.01M
YoY Change	-262.6%	-122.53%	-109.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net			$0.00
YoY Change
Cash From Financing Activities	15.05M	10.04M	35.09M
YoY Change	40.66%	34.77%	-94.56%
NET CHANGE
Cash From Operating Activities	-6.320M	18.12M	29.87M
Cash From Investing Activities	-11.93M	9.540M	25.01M
Cash From Financing Activities	15.05M	10.04M	35.09M
Net Change In Cash	-3.195M	37.70M	89.98M
YoY Change	-131.49%	-216.29%	-76.52%
FREE CASH FLOW
Cash From Operating Activities	-$6.320M	$18.12M	$29.87M
Capital Expenditures	$962.0K	-$3.390M	$3.510M
Free Cash Flow	-$7.282M	$21.51M	$26.36M
YoY Change	-13.95%	298.33%	-397.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiabilityCurrent
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiabilityCurrent
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72761941
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70516249
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2018Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001477449
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiability
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-37477
CY2019	dei	Entity Registrant Name EntityRegistrantName	TELADOC HEALTH, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3705970
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Manhattanville Road
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 203
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Purchase
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10577
CY2019	dei	City Area Code CityAreaCode	203
CY2019	dei	Local Phone Number LocalPhoneNumber	635-2002
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2019	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.004
CY2019	dei	Trading Symbol TradingSymbol	TDOC
CY2019	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56948000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43571000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13990000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10631000
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	4607261555
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73008312
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	514353000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	423989000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	2711000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	54545000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3787000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3382000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	588002000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	532736000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10296000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10148000
CY2019Q4	us-gaap	Goodwill Goodwill	746079000
CY2018Q4	us-gaap	Goodwill Goodwill	737197000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	225453000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	247394000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26452000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6545000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1401000
CY2019Q4	us-gaap	Assets Assets	1602827000
CY2018Q4	us-gaap	Assets Assets	1528876000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9075000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7769000
CY2019Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	49848000
CY2018Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	26801000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31258000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27869000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	90181000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62439000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11539000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6191000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24994000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	21678000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	32444000
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	440410000
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	414683000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72761941
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70516249
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	73000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	70000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1538716000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1434780000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507525000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-408661000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17239000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13070000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1014025000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1013119000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1602827000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1528876000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	553307000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	417907000
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	233279000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	184465000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	128735000
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	61623000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	109697000
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	85109000
CY2017	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	57663000
CY2019	us-gaap	Selling Expense SellingExpense	64915000
CY2018	us-gaap	Selling Expense SellingExpense	59154000
CY2017	us-gaap	Selling Expense SellingExpense	37984000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64644000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54373000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34459000
CY2019	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	6762000
CY2018	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	3981000
CY2017	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	4872000
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	6620000
CY2018	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	10391000
CY2017	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	13196000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5500000
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	157694000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	116916000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79781000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10931000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3659000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2685000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2612000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2003000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	105000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	414000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38952000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	35602000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19095000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	633749000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	488761000
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	308673000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-80442000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-70854000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-75394000
CY2019	tdoc	Amortization Of Warrants And Loss On Extinguishment Of Debt AmortizationOfWarrantsAndLossOnExtinguishmentOfDebt	0
CY2018	tdoc	Amortization Of Warrants And Loss On Extinguishment Of Debt AmortizationOfWarrantsAndLossOnExtinguishmentOfDebt	0
CY2017	tdoc	Amortization Of Warrants And Loss On Extinguishment Of Debt AmortizationOfWarrantsAndLossOnExtinguishmentOfDebt	14122000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-29013000
CY2018	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-26112000
CY2017	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-17491000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109455000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96966000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107007000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10591000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-225000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-106782000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.93
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71844535
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65844908
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55427460
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-106782000
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	32000
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	20000
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-51000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4201000
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-17179000
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4141000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4169000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-17159000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4090000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-103033000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114243000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102692000
CY2016Q4	tdoc	Stockholders Equity Total StockholdersEquityTotal	230870000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10837000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2153000
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	68564000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43769000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17159000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2018Q4	tdoc	Stockholders Equity Total StockholdersEquityTotal	1013119000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33275000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3380000
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2564000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67276000
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	66180000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	62404000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30597000
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	258554000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4090000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-106782000
CY2017Q4	tdoc	Stockholders Equity Total StockholdersEquityTotal	558903000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31322000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	91397000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	330843000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4169000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2019Q4	tdoc	Stockholders Equity Total StockholdersEquityTotal	1014025000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-106782000
CY2019	tdoc	Depreciation And Amortization Including Rou Assets DepreciationAndAmortizationIncludingRouAssets	44952000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35602000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19095000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2665000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2243000
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1731000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	66702000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	43769000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	30597000
CY2019	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-10868000
CY2018	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-2247000
CY2017	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-306000
CY2019	tdoc	Accretion Of Interest AccretionOfInterest	25438000
CY2018	tdoc	Accretion Of Interest AccretionOfInterest	19487000
CY2017	tdoc	Accretion Of Interest AccretionOfInterest	6382000
CY2019	tdoc	Amortization Of Warrants And Gain Loss On Extinguishment Of Debt AmortizationOfWarrantsAndGainLossOnExtinguishmentOfDebt	0
CY2018	tdoc	Amortization Of Warrants And Gain Loss On Extinguishment Of Debt AmortizationOfWarrantsAndGainLossOnExtinguishmentOfDebt	0
CY2017	tdoc	Amortization Of Warrants And Gain Loss On Extinguishment Of Debt AmortizationOfWarrantsAndGainLossOnExtinguishmentOfDebt	14122000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5500000
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15884000
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-98000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	905000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-391000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1534000
CY2019	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	14841000
CY2018	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	3993000
CY2017	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	4292000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4546000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8480000
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3768000
CY2019	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2417000
CY2018	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0
CY2017	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	643000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	745000
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3310000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29869000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4860000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34441000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3510000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4011000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2633000
CY2019	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	7390000
CY2018	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	4396000
CY2017	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	2882000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	56347000
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	149261000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52100000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	84170000
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	85753000
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5530000
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2019	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5000000
CY2018	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
CY2017	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11187000
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	282442000
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	379356000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25013000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-257496000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-448379000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33283000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31322000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10837000
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	279152000
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	263722000
CY2019	tdoc	Proceeds From Issuance Of Bank And Other Debt ProceedsFromIssuanceOfBankAndOtherDebt	0
CY2018	tdoc	Proceeds From Issuance Of Bank And Other Debt ProceedsFromIssuanceOfBankAndOtherDebt	10000
CY2017	tdoc	Proceeds From Issuance Of Bank And Other Debt ProceedsFromIssuanceOfBankAndOtherDebt	166679000
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	226440000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	330843000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	258554000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3380000
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2564000
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2153000
CY2019	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-1569000
CY2018	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	1721000
CY2017	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-74000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35094000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	645612000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	475431000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	89976000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	383256000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7389000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	388000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2084000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	191000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	423989000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42817000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50015000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	514353000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	423989000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42817000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1310000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	441000
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	137000
CY2019	us-gaap	Interest Paid InterestPaid	12224000
CY2018	us-gaap	Interest Paid InterestPaid	10303000
CY2017	us-gaap	Interest Paid InterestPaid	9450000
CY2018Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	167000
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2810000
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	644000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5088000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2018Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TELADOC HEALTH, INC.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Audited Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc” or the “Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in providing virtual healthcare services with a focus on high quality, lower costs, and improved outcomes around the world. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company completed the acquisition of MedecinDirect, on April 30, 2019, a Paris-based telemedicine provider, Advance Medical-Health Care Management Services, S.A. (“Advance Medical”), in May 2018, a leading global virtual healthcare provider, Best Doctors Holdings, Inc. (“Best Doctors”), in July 2017, an expert medical consultation company focused on improving health outcomes for the most complex, critical and costly medical issues.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On July 26, 2018, Teladoc Health completed a follow-on public offering (the “July Offering”) in which the Company issued and sold 5,000,000 shares of common stock, at an issuance price of $66.28 per share. The Company received net proceeds of $330.9 million after deducting offering expenses of $0.5 million.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On May 8, 2018, the Company issued, at par value, $287.5 million aggregate principal amount of 1.375% convertible senior notes due 2025 (the “2025 Notes”). The 2025 Notes bear cash interest at a rate of 1.375% per year, payable semi-annually in arrears on May 15 and November 15 of each year. The 2025 Notes will mature on May 15, 2025. The net proceeds to the Company from the offering were $279.1 million after deducting offering costs of approximately $8.4 million.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On December 4, 2017, Teladoc Health completed a follow on public offering (the “December Offering”) in which the Company issued and sold 4,096,600 shares of common stock at an issuance price of $35.00 per share. The Company received net proceeds of $134.7 million after deducting underwriting discounts and commissions of $8.2 million as well as other offering expenses of $0.5 million. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On June 27, 2017, the Company issued, at par value, $275 million aggregate principal amount of 3% convertible senior notes due 2022 (the “2022 Notes”). The 2022 Notes bear cash interest at a rate of 3% per year, payable semi-annually in arrears on June 15 and December 15 of each year. The 2022 Notes will mature on December 15, 2022. The net proceeds to the Company from the offering were $263.7 million after deducting offering costs of approximately $11.3 million. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On January 24, 2017, Teladoc Health completed a follow on public offering (the “January Offering”) in which the Company issued and sold 7,887,500 shares of common stock at an issuance price of $16.75 per share. The Company received net proceeds of $123.9 million after deducting underwriting discounts and commissions of $7.6 million as well as other offering expenses of $0.6 million.</p>
CY2019	tdoc	Number Of Professional Associations Consolidated As Variable Interest Entities NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities	2
CY2019	tdoc	Number Of Professional Corporations Consolidated As Variable Interest Entities NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities	14
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the carrying value, capitalization and amortization of software development costs, purchase accounting, client performance guarantees, the calculation of a contingent liability in connection with an earn-out, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2019	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-100000
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12466000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7650000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7996000
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	200000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	100000
CY2018Q4	tdoc	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	26801000
CY2019	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warranties and Indemnification</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company’s arrangements generally include certain provisions for indemnifying Clients against liabilities if there is a breach of a Client’s data or if the Company’s service infringes a third party’s intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by the Company, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.</p>
CY2019	us-gaap	Advertising Expense AdvertisingExpense	88800000
CY2018	us-gaap	Advertising Expense AdvertisingExpense	70600000
CY2017	us-gaap	Advertising Expense AdvertisingExpense	45100000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Risk and Significant Clients</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. Although the Company deposits its cash with multiple financial institutions in U.S. and in foreign countries, its deposits, at times, may exceed federally insured limits. The Company’s short-term investments are comprised of a portfolio of diverse high credit rating instruments with maturity durations of one year or less.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Revenue from Clients located in the United States for the year ended December 31, 2019, 2018 and 2017 were $445.3 million, $342.7 million and $214.5 million, respectively. Revenue from Clients located outside the United States for the year ended December 31, 2019, 2018 and 2017 were $108.0 million, $75.2 million and $18.8 million, respectively.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Certain prior year amounts have been reclassified to conform to the current year presentation.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2019	tdoc	Contract With Customer Term ContractWithCustomerTerm	P1Y
CY2019	tdoc	Payment Terms PaymentTerms	P30D
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	553307000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	417907000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56900000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43600000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7100000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3600000
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7100000
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000.0
CY2019	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	3300000
CY2018	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	2700000
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	553307000
CY2018	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	447573000
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-98864000
CY2018	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-94314000
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3031000
CY2019Q4	tdoc	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	49848000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26058000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22431000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15762000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12283000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10296000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10148000
CY2019	us-gaap	Depreciation Depreciation	3400000
CY2018	us-gaap	Depreciation Depreciation	4100000
CY2017	us-gaap	Depreciation Depreciation	3800000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	319796000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	94343000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	225453000
CY2019	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P12Y4M24D
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	305658000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	58264000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	247394000
CY2018	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P13Y2M12D
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	35600000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31500000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15300000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	34728000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	30627000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	25479000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20982000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	113637000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	225453000
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	838000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	883000
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2859000
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2610000
CY2019Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1263000
CY2018Q4	us-gaap	Goodwill Goodwill	737197000
CY2017Q4	us-gaap	Goodwill Goodwill	498520000
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	10604000
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	250120000
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1722000
CY2018	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-11443000
CY2019Q4	us-gaap	Goodwill Goodwill	746079000
CY2018Q4	us-gaap	Goodwill Goodwill	737197000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1535000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1264000
CY2019Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	10618000
CY2018Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	6569000
CY2019Q4	tdoc	Other Current Liabilities Clients Guarantees OtherCurrentLiabilitiesClientsGuarantees	3298000
CY2018Q4	tdoc	Other Current Liabilities Clients Guarantees OtherCurrentLiabilitiesClientsGuarantees	2910000
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1077000
CY2018Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1073000
CY2019	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	8020000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	954000
CY2019	us-gaap	Lease Cost LeaseCost	8974000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	7911000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6228000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8019000
CY2018	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.013
CY2017	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.115
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.165
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7030000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5890000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5751000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5477000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4382000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	36549000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6467000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	30082000
CY2019Q4	tdoc	Operating Lease Commitment Commencing Next Fiscal Year Amount OperatingLeaseCommitmentCommencingNextFiscalYearAmount	8000000.0
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	2200000
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2018
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.80
CY2019	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodIntrinsicValue	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	76624
CY2018	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue	38.55
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	486441
CY2019	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue	64.94
CY2019	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndIssued	31338
CY2019	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Issued Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndIssuedWeightedAverageGrantDateFairValue	38.55
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	19245
CY2019	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsWeightedAverageGrantDateFairValue	67.55
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	512482
CY2019Q4	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue	62.51
CY2019Q4	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableNumber	0
CY2019Q4	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageGrantDateFairValue	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	512482
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	62.51
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66702000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43769000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30597000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-95476000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-91142000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-107703000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13979000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5824000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	696000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109455000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96966000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107007000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.066
CY2019	tdoc	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	-0.038
CY2018	tdoc	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	0
CY2017	tdoc	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.022
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	239000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	9000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	300000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-262000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2011000
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	357000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	277000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2017000
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	366000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5043000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-499000
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-273000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1783000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	416000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	122000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4042000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1816000
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-440000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10868000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1899000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-591000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10591000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-225000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.046
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	-0.032
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.012
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.345
CY2019	tdoc	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRateValuationAllowance	0
CY2018	tdoc	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRateValuationAllowance	0
CY2017	tdoc	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRateValuationAllowance	0.353
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.415
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.431
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.006
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.097
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	158520000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	136384000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2168000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	782000
CY2019Q4	tdoc	Deferred Tax Assets Uncertain Tax Positions DeferredTaxAssetsUncertainTaxPositions	352000
CY2018Q4	tdoc	Deferred Tax Assets Uncertain Tax Positions DeferredTaxAssetsUncertainTaxPositions	312000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14914000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9175000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	5871000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	7135000
CY2019Q4	tdoc	Deferred Tax Assets Interest Expenses Carryforward DeferredTaxAssetsInterestExpensesCarryforward	1295000
CY2018Q4	tdoc	Deferred Tax Assets Interest Expenses Carryforward DeferredTaxAssetsInterestExpensesCarryforward	1274000
CY2019Q4	tdoc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	7492000
CY2018Q4	tdoc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	0
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	127000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	73000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	190739000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	155135000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	121186000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93572000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	69553000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	61563000
CY2019Q4	tdoc	Deferred Tax Liabilities Debt Restructure Costs DeferredTaxLiabilitiesDebtRestructureCosts	27545000
CY2018Q4	tdoc	Deferred Tax Liabilities Debt Restructure Costs DeferredTaxLiabilitiesDebtRestructureCosts	31986000
CY2019Q4	tdoc	Deferred Tax Liabilities Operating Lease Liabilities DeferredTaxLiabilitiesOperatingLeaseLiabilities	6889000
CY2018Q4	tdoc	Deferred Tax Liabilities Operating Lease Liabilities DeferredTaxLiabilitiesOperatingLeaseLiabilities	0
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1344000
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2342000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	55453000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	59679000
CY2018Q4	us-gaap	Selling Expense SellingExpense	14509000
CY2019Q1	us-gaap	Selling Expense SellingExpense	16212000
CY2019Q2	us-gaap	Selling Expense SellingExpense	15832000
CY2019Q3	us-gaap	Selling Expense SellingExpense	16120000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	91231000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	94007000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	21678000
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	32444000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	121200000
CY2019	tdoc	Acquisition Valuation Allowance Deferred Tax Asset Change In Amount AcquisitionValuationAllowanceDeferredTaxAssetChangeInAmount	27600000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019Q4	tdoc	Interest Expenses Carryforward InterestExpensesCarryforward	5200000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2907000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	5000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2912000
CY2019Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	2400000
CY2019Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	12800000
CY2018Q2	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5500000
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5500000
CY2019Q4	us-gaap	Selling Expense SellingExpense	16751000
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12904000
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14348000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13577000
CY2018Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13544000
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15987000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16665000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-106782000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71845000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65845000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55427000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.93
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	89644000
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	94560000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	110962000
CY2018Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	122741000
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	128573000
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	130276000
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	137969000
CY2019Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	156489000
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26856000
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27684000
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	34167000
CY2018Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40028000
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	44677000
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41634000
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42799000
CY2019Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55355000
CY2018Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	20325000
CY2018Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	19561000
CY2018Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	21668000
CY2018Q4	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	23555000
CY2019Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	26404000
CY2019Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	26616000
CY2019Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	31321000
CY2019Q4	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	25356000
CY2018Q1	us-gaap	Selling Expense SellingExpense	13783000
CY2018Q2	us-gaap	Selling Expense SellingExpense	14559000
CY2018Q3	us-gaap	Selling Expense SellingExpense	16303000
CY2018Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1588000
CY2018Q4	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1434000
CY2019Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1012000
CY2019Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1136000
CY2019Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1995000
CY2019Q4	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2477000
CY2018Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4070000
CY2018Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1430000
CY2018Q4	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	152299000
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	157913000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15746000
CY2019Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16246000
CY2018Q1	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	1045000
CY2018Q2	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	639000
CY2018Q3	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	807000
CY2018Q4	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	1490000
CY2019Q1	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	1586000
CY2019Q2	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	2019000
CY2019Q3	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	1634000
CY2019Q4	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	1523000
CY2018Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1569000
CY2018Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5800000
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019Q4	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24001000
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26140000
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30314000
CY2018Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36461000
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35982000
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38549000
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38681000
CY2019Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44482000
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8253000
CY2018Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8046000
CY2018Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9746000
CY2018Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9557000
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9600000
CY2019Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9848000
CY2019Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9617000
CY2019Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9887000
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	108736000
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	112707000
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	126740000
CY2018Q4	us-gaap	Costs And Expenses CostsAndExpenses	140578000
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	151460000
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-7700000
CY2019Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-7581000
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23965000
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25057000
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23444000
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24500000
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	172077000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19092000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18147000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15778000
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-17837000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22887000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22023000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19944000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-15588000
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4873000
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6910000
CY2018Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-7666000
CY2018Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6663000
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6521000
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-7211000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29408000
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29234000
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27644000
CY2019Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23169000
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-103000
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-180000
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	379000
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	742000
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7298000
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4125000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-23862000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-25079000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-23264000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-24879000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-30150000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-29324000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-20346000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-19044000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61798000
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62976000
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68248000
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70240000
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70919000
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71721000
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72151000
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72565000
CY2019	tdoc	Minimum Age Of Employee Eligible Under Plan MinimumAgeOfEmployeeEligibleUnderPlan	P21Y
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	300000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2700000
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1700000

Files In Submission

Name	View Source	Status
0001558370-20-001473-index-headers.html	Edgar Link	pending
0001558370-20-001473-index.html	Edgar Link	pending
0001558370-20-001473.txt	Edgar Link	pending
0001558370-20-001473-xbrl.zip	Edgar Link	pending
ex-10d16.htm	Edgar Link	pending
ex-10d16g001.gif	Edgar Link	pending
ex-10d16g002.gif	Edgar Link	pending
ex-10d16g003.gif	Edgar Link	pending
ex-10d28.htm	Edgar Link	pending
ex-10d28g001.gif	Edgar Link	pending
ex-10d28g002.gif	Edgar Link	pending
ex-10d28g003.gif	Edgar Link	pending
ex-10d28g004.gif	Edgar Link	pending
ex-10d28g005.gif	Edgar Link	pending
ex-10d28g006.gif	Edgar Link	pending
ex-10d28g007.gif	Edgar Link	pending
ex-10d28g008.gif	Edgar Link	pending
ex-10d28g009.gif	Edgar Link	pending
ex-10d28g010.gif	Edgar Link	pending
ex-10d28g011.gif	Edgar Link	pending
ex-10d28g012.gif	Edgar Link	pending
ex-10d30.htm	Edgar Link	pending
ex-10d30g001.gif	Edgar Link	pending
ex-10d30g002.gif	Edgar Link	pending
ex-10d30g003.gif	Edgar Link	pending
ex-10d30g004.gif	Edgar Link	pending
ex-10d30g005.gif	Edgar Link	pending
ex-10d30g006.gif	Edgar Link	pending
ex-10d30g007.gif	Edgar Link	pending
ex-10d30g008.gif	Edgar Link	pending
ex-10d30g009.gif	Edgar Link	pending
ex-10d30g010.gif	Edgar Link	pending
ex-10d30g011.gif	Edgar Link	pending
ex-10d30g012.gif	Edgar Link	pending
ex-10d30g013.gif	Edgar Link	pending
ex-10d30g014.gif	Edgar Link	pending
ex-10d30g015.gif	Edgar Link	pending
ex-10d30g016.gif	Edgar Link	pending
ex-10d30g017.gif	Edgar Link	pending
ex-10d30g018.gif	Edgar Link	pending
ex-10d30g019.gif	Edgar Link	pending
ex-10d32.htm	Edgar Link	pending
ex-10d32g001.gif	Edgar Link	pending
ex-10d32g002.gif	Edgar Link	pending
ex-10d32g003.gif	Edgar Link	pending
ex-10d32g004.gif	Edgar Link	pending
ex-10d32g005.gif	Edgar Link	pending
ex-10d32g006.gif	Edgar Link	pending
ex-10d32g007.gif	Edgar Link	pending
ex-10d32g008.gif	Edgar Link	pending
ex-10d32g009.gif	Edgar Link	pending
ex-10d32g010.gif	Edgar Link	pending
ex-10d32g011.gif	Edgar Link	pending
ex-10d32g012.gif	Edgar Link	pending
ex-10d32g013.gif	Edgar Link	pending
ex-10d32g014.gif	Edgar Link	pending
ex-10d32g015.gif	Edgar Link	pending
ex-10d32g016.gif	Edgar Link	pending
ex-10d32g017.gif	Edgar Link	pending
ex-10d32g018.gif	Edgar Link	pending
ex-10d32g019.gif	Edgar Link	pending
ex-10d32g020.gif	Edgar Link	pending
ex-10d34.htm	Edgar Link	pending
ex-10d34g001.gif	Edgar Link	pending
ex-10d34g002.gif	Edgar Link	pending
ex-10d34g003.gif	Edgar Link	pending
ex-10d34g004.gif	Edgar Link	pending
ex-10d34g005.gif	Edgar Link	pending
ex-10d34g006.gif	Edgar Link	pending
ex-10d34g007.gif	Edgar Link	pending
ex-10d34g008.gif	Edgar Link	pending
ex-10d34g009.gif	Edgar Link	pending
ex-10d34g010.gif	Edgar Link	pending
ex-10d34g011.gif	Edgar Link	pending
ex-10d34g012.gif	Edgar Link	pending
ex-10d34g013.gif	Edgar Link	pending
ex-10d34g014.gif	Edgar Link	pending
ex-10d34g015.gif	Edgar Link	pending
ex-10d34g016.gif	Edgar Link	pending
ex-10d34g017.gif	Edgar Link	pending
ex-10d34g018.gif	Edgar Link	pending
ex-10d34g019.gif	Edgar Link	pending
ex-10d34g020.gif	Edgar Link	pending
ex-21d1.htm	Edgar Link	pending
ex-23d1.htm	Edgar Link	pending
ex-23d1g001.jpg	Edgar Link	pending
ex-31d1.htm	Edgar Link	pending
ex-31d2.htm	Edgar Link	pending
ex-32d1.htm	Edgar Link	pending
ex-32d2.htm	Edgar Link	pending
ex-4d6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tdoc-20181231.xsd	Edgar Link	pending
tdoc-20181231x10kba26f9.htm	Edgar Link	pending
tdoc-20181231x10kba26f9004.jpg	Edgar Link	pending
tdoc-20181231x10kba26f9_htm.xml	Edgar Link	completed
tdoc-20181231_cal.xml	Edgar Link	unprocessable
tdoc-20181231_def.xml	Edgar Link	unprocessable
tdoc-20181231_lab.xml	Edgar Link	unprocessable
tdoc-20181231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TDOC
Teladoc Health, Inc. Stock $tdoc

2020 Q1 Form 10-K Financial Statement

#000155837020001473 Filed on February 26, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC Teladoc Health, Inc. Stock $tdoc

2020 Q1 Form 10-K Financial Statement

#000155837020001473 Filed on February 26, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC
Teladoc Health, Inc. Stock $tdoc